[{"id":"21a8be08-eefa-4035-aec2-4a3752975586","acronym":"IPATunity130","url":"https://clinicaltrials.gov/study/NCT03337724","created_at":"2021-01-17T17:26:41.567Z","updated_at":"2024-07-02T16:35:15.265Z","phase":"Phase 3","brief_title":"A Study of Ipatasertib in Combination With Paclitaxel as a Treatment for Participants With PIK3CA/AKT1/PTEN-Altered, Locally Advanced or Metastatic, Triple-Negative Breast Cancer or Hormone Receptor-Positive, HER2-Negative Breast Cancer","source_id_and_acronym":"NCT03337724 - IPATunity130","lead_sponsor":"Hoffmann-La Roche","biomarkers":" HER-2 • PIK3CA • PTEN • AKT1","pipe":" | ","alterations":" HER-2 negative","tags":["HER-2 • PIK3CA • PTEN • AKT1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HER-2 negative"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e paclitaxel • ipatasertib (RG7440)"],"overall_status":"Completed","enrollment":" Enrollment 579","initiation":"Initiation: 01/06/2018","start_date":" 01/06/2018","primary_txt":" Primary completion: 01/04/2023","primary_completion_date":" 01/04/2023","study_txt":" Completion: 01/04/2023","study_completion_date":" 01/04/2023","last_update_posted":"2024-03-12"},{"id":"67594d86-d6cf-4b01-aefe-6548477c2d62","acronym":"EMR100018-001","url":"https://clinicaltrials.gov/study/NCT01971515","created_at":"2021-01-18T08:58:11.943Z","updated_at":"2024-07-02T16:37:06.726Z","phase":"Phase 1","brief_title":"First-in-Human Dose Escalation Trial in Subjects With Advanced Malignancies","source_id_and_acronym":"NCT01971515 - EMR100018-001","lead_sponsor":"EMD Serono","biomarkers":" HER-2 • ER • PIK3CA • PGR • PTEN • AKT1 • mTOR • TSC2 • TSC1 • AKT2","pipe":" | ","alterations":" HR positive • HER-2 negative • PGR positive","tags":["HER-2 • ER • PIK3CA • PGR • PTEN • AKT1 • mTOR • TSC2 • TSC1 • AKT2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HR positive • HER-2 negative • PGR positive"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Herceptin (trastuzumab) • tamoxifen • rupitasertib (DIACC3010)"],"overall_status":"Completed","enrollment":" Enrollment 101","initiation":"Initiation: 12/13/2013","start_date":" 12/13/2013","primary_txt":" Primary completion: 08/09/2018","primary_completion_date":" 08/09/2018","study_txt":" Completion: 08/09/2018","study_completion_date":" 08/09/2018","last_update_posted":"2018-09-19"},{"id":"315599d2-2faa-4fa8-9734-19252ebf4382","acronym":"","url":"https://clinicaltrials.gov/study/NCT01915576","created_at":"2021-01-18T08:38:20.529Z","updated_at":"2025-02-25T17:06:56.587Z","phase":"Phase 1","brief_title":"Phase I Dose Escalation Study With an Allosteric AKT 1/2 Inhibitor in Patients","source_id_and_acronym":"NCT01915576","lead_sponsor":"Bayer","biomarkers":" AKT1","pipe":" | ","alterations":" AKT1 E17K • AKT1 mutation","tags":["AKT1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e AKT1 E17K • AKT1 mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e BAY 1125976"],"overall_status":"Completed","enrollment":" Enrollment 79","initiation":"Initiation: 09/01/2013","start_date":" 09/01/2013","primary_txt":" Primary completion: 07/01/2016","primary_completion_date":" 07/01/2016","study_txt":" Completion: 12/01/2016","study_completion_date":" 12/01/2016","last_update_posted":"2016-12-28"}]